Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
57
Recruiting, any sponsor type, condition "nausea and vomiting"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed566
57 trials
Showing 1 to 25, recently updated first.
- Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION)Pivotal-lookingRecruiting
Telethon Kids InstituteAcademic, hospital or other
NCT07777276 · 500 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 17, 2029
Drug: Dexamethasone (IV); Ondansetron iv · For: Postoperative Sleep Quality; Postoperative Behaviour; Postoperative Recovery in Children and 3 more
Sites: Perth, Australia; São Paulo, Brazil · 3 sites in all
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryPivotal-lookingRecruiting
Sir Mortimer B. Davis - Jewish General HospitalAcademic, hospital or other
NCT07371728 · 100 participants (planned) · Start Oct 15, 2026 · Primary completion Jun 1, 2027
Drug: Aprepitant · For: Otologic Disease
Sites: Montreal, Canada
Kayseri City HospitalGovernment (non-federal)
NCT07861737 · 80 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2026
Drug: Granisetron · For: Hypotension; Nausea; Vomiting and 1 more
Sites: Kayseri, Turkey (Türkiye)
University of Illinois ChicagoAcademic, hospital or other
NCT04150614 · 90 participants (planned) · Start May 14, 2020 · Primary completion Mar 2027
Drug: Granisetron Transdermal Patch; Intravenous Dexamethasone and 1 more · For: Nausea With Vomiting Chemotherapy-Induced
Sites: Chicago, Illinois
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07169851 · 204 participants (planned) · Start Nov 28, 2025 · Primary completion Dec 2026
Drug: LY3537021; Placebo and 2 more · For: Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions and 1 more
Sites: Greenbrae, California; Irvine, California; Los Alamitos, California · 67 sites in all
Chinese University of Hong KongAcademic, hospital or other
NCT07455955 · 60 participants (planned) · Start Mar 31, 2026 · Primary completion Jun 3, 2027
Drug: Standard antiemetic regimen or Olanzapine antiemetic regimen · For: Breast Cancer
Sites: Hong Kong, Hong Kong
- Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07681076 · 180 participants (planned) · Start Sep 3, 2026 · Primary completion Nov 30, 2026
Drug: KarXT; Trimethobenzamide and 2 more · For: Healthy Volunteers
Sites: Los Alamitos, California; Hollywood, Florida; Atlanta, Georgia · 4 sites in all
Nasus PharmaIndustry
NCT07868861 · 12 participants (planned) · Start Sep 15, 2026 · Primary completion Jan 2027
Drug: NS003 Ondansetron HCl microspheres powder for nasal application; Ondansetron Solution for IV infusion 8mg · For: Chemotherapy-Induced Nausea and Vomiting (CINV); Radiotherapy-induced Nausea and Vomiting (RINV); Postoperative Nausea and Vomiting
Sites: Jerusalem, Israel
- Routine Antiemetic Prophylaxis for Nonfasted Parturients Undergoing Cesarean Sections Under Spinal AnesthesiaPivotal-lookingRecruiting
Sanliurfa Education and Research HospitalGovernment (non-federal)
NCT07740577 · 120 participants (planned) · Start Jul 30, 2026 · Primary completion Jan 1, 2027
Drug: Ondansetron 4mg; metoclopramide · For: Intraoperative Nausea-retching-vomiting Episodes; Spinal Aneshtesia; Ceserean Section and 3 more
Sites: Sanliurfa, Turkey (Türkiye)
- Effects of taVNS Combined With Dexmedetomidine on POVNPivotal-lookingRecruiting
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
NCT07271147 · 176 participants (planned) · Start Dec 7, 2025 · Primary completion Dec 1, 2026
Drug: Dexmedetomidine · For: Postoperative Nausea and Vomiting
Sites: Nantong, China
Helsinn Healthcare SAIndustry
NCT06904235 · 95 participants (planned) · Start Jul 7, 2025 · Primary completion Oct 2027
Drug: IV NEPA (fosnetupitant/palonosetron); Reference Treatment: IV ondansetron infusion and 1 more · For: Nausea and Vomiting Chemotherapy-Induced; Nausea Post Chemotherapy
Sites: Athens, Greece; Thessaloniki, Greece; Bialystok, Poland · 20 sites in all
- Inhaled Isopropyl Alcohol for Treatment of NauseaPivotal-lookingRecruiting
State University of New York at BuffaloAcademic, hospital or other
NCT05418244 · 84 participants (planned) · Start Apr 20, 2022 · Primary completion Jun 30, 2027
Drug: Oral Ondansetron · For: Vomiting; Nausea; Children, Only
Sites: Buffalo, New York
Filiz KayaAcademic, hospital or other
NCT07812389 · 104 participants (planned) · Start Aug 15, 2026 · Primary completion Aug 15, 2027
Drug: Dexmedetomidine; Remifentanil · For: Chronic Sinusitis; Postoperative Pain; Postoperative Nausea and Vomiting (PONV) and 5 more
Sites: Ankara, Turkey (Türkiye)
- Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic CholecystectomyPivotal-lookingRecruiting
Faisalabad Medical UniversityAcademic, hospital or other
NCT07638527 · 264 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Drug: ondansetron 4 mg; Dexamethasone (intravenous) and 1 more · For: Postoperative Nausea and Vomiting
Sites: Faisalābad, Pakistan
- A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and VomitingPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07709897 · 260 participants (planned) · Start Aug 6, 2026 · Primary completion Dec 2026
Drug: HRS5580 for injection combined with palonosetron hydrochloride;; HRS5580 for injection combined with palonosetron hydrochloride and 1 more · For: Prevention of Postoperative Nausea and Vomiting
Sites: Shanghai, China; Tianjin, China
- MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in ChildrenPivotal-lookingRecruiting
Arash AfshariAcademic, hospital or other
NCT05541276 · 676 participants (planned) · Start Jan 21, 2025 · Primary completion Mar 1, 2027
Drug: Melatonin; Isotonic sodium chloride solution · For: Emergence Delirium
Sites: Copenhagen, Denmark
Xiu HuangAcademic, hospital or other
NCT07768124 · 60 participants (planned) · Start Jul 15, 2026 · Primary completion Oct 15, 2026
Drug: 5-HT3 receptor antagonist (e.g., ondansetron) · For: Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting
Sites: Chongqing, China
- The PREVENT AGITATION Trial II - Children ≤1 YearPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05091242 · 336 participants (planned) · Start Oct 25, 2021 · Primary completion Jan 31, 2028
Drug: Clonidine; Sodium chloride · For: Emergence Delirium
Sites: Perth, Australia; Copenhagen, Denmark
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07726433 · 56 participants (planned) · Start Jun 15, 2026 · Primary completion Jun 1, 2028
Drug: Fosrolapitant and Palonosetron Hydrochloride for Injection · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
Sites: Tianjin, China
University of Southern CaliforniaAcademic, hospital or other
NCT07129473 · 224 participants (planned) · Start Jul 13, 2026 · Primary completion Mar 2031
Drug: Metformin Extended Release Oral Tablet · For: Hyperemesis Gravidarum
Sites: Birmingham, Alabama; Los Angeles, California
- Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs OxycodonePivotal-lookingRecruiting
Murdoch Childrens Research InstituteAcademic, hospital or other
NCT06186141 · 690 participants (planned) · Start Mar 13, 2024 · Primary completion Dec 2027
Drug: Morphine; Oxycodone · For: Patient-Controlled Analgesia
Sites: Melbourne, Australia
- Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus CyclophosphamidePivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07716176 · 74 participants (planned) · Start Dec 12, 2025 · Primary completion Dec 6, 2026
Drug: Auricular point stimulation plus dexamethasone; Standard pharmacologic antiemetic regimen · For: Nausea and Vomiting Caused by Chemotherapy
Sites: Hangzhou, China
- Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-boundPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07716228 · 74 participants (planned) · Start Dec 12, 2025 · Primary completion Dec 6, 2026
Drug: Auricular point stimulation plus dexamethasone; Standard pharmacologic antiemetic regimen · For: Nausea and Vomiting Caused by Chemotherapy
Sites: Hangzhou, China
- Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab DeruxtecanPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07716189 · 74 participants (planned) · Start Dec 12, 2025 · Primary completion Dec 6, 2026
Drug: Auricular point stimulation plus dexamethasone; Standard pharmacologic antiemetic regimen · For: Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Sites: Hangzhou, China
Mahidol UniversityAcademic, hospital or other
NCT07699276 · 95 participants (planned) · Start Feb 10, 2026 · Primary completion Oct 1, 2027
Drug: dexamethasone sparing · For: Cancer (Solid Tumors); Vomiting; Cisplatin and 1 more
Sites: Bangkok, Thailand
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.